Beatriz Blanco

Beatriz Blanco

Auto-generated profile, based on publicly available information

Beatriz Blanco

School of Physical Sciences, University of Adelaide, South Australia 5005, Australia

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2013 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
BBBeatriz Blanco
Beatriz Blanco
VPVerónica Prado
Verónica Prado
ELEmilio Lence
Emilio Lence
JOJosé M. Otero
José M. Otero
CGCarmela Garcia-Doval
Carmela Garcia-Doval
Concepción González-BelloConcepción González-Bello
Concepción González-Bello

1 February 2014 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
HSHajime Seki
Hajime Seki
SPSabine Pellett
Sabine Pellett
PŠPeter Šilhár
Peter Šilhár
GSG. Neil Stowe
G. Neil Stowe
BBBeatriz Blanco
Beatriz Blanco
KJKim D Janda
Kim D Janda

5 March 2012 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
BBBeatriz Blanco
Beatriz Blanco
ASAntía Sedes
Antía Sedes
APAntonio Peón
Antonio Peón
HLHeather Lamb
Heather Lamb
AHAlastair R. Hawkins
Alastair R. Hawkins
Concepción González-BelloConcepción González-Bello
Concepción González-Bello
Several 3-alkylaryl mimics of the enol intermediate in the reaction catalyzed by type II dehydroquinase were synthesized to investigate the effect on the inhibition potency of replacing the oxygen atom in the side chain by a carbon atom. The length and the rigidity of the spacer was also studied. The inhibitory properties of the reported compounds against type II dehydroquinase from Mycobacterium tuberculosis and Helicobacter pylori are also reported. The binding modes of these analogs in the active site of both enzymes were studied by molecular docking using GOLD 5.0 and dynamic simulations studies.

4 June 2019 in Organic Chemistry Frontiers
Verified
Journal Article
Open access
PDF file
MPMarina Pernas
Marina Pernas
BBBeatriz Blanco
Beatriz Blanco
ELEmilio Lence
Emilio Lence
PTPaul Thompson
Paul Thompson
AHAlastair R. Hawkins
Alastair R. Hawkins
Concepción González-BelloConcepción González-Bello
Concepción González-Bello
Diverse rigidified shikimic acids derivatives, which are stable mimetics of the high-energy conformation of shikimic acid, have been synthesized to enhance inhibitor efficacy against shikimate kinase enzyme (SK), an attractive target for antibiotic drug discovery. The synthesis of the reported conformationally restricted shikimic acid derivatives was carried out by ring-closing metathesis of allyloxy vinyl derivatives as the key step. The rigidification of the ligand conformation was used to maximize the effectiveness of the substituents introduced in the ether carbon bridge of the scaffold by pre-orienting their interaction with key residues and enzyme domains that are essential for catalysis and enzyme motion. Molecular Dynamics simulation studies on the enzyme/ligand complexes revealed marked differences in the positioning of the ligand substituent in the active site of the two enzymes studied (SK from Mycobacterium tuberculosis and Helicobacter pylori) and this explains their greater efficacy against one of the enzymes. This enhancement is due to the distinct induced-fit motion of the two homologous enzymes. A 20-fold improvement against the H. pylori enzyme was achieved by the introduction of a CH2OEt group in the rigid ether bridge of the reported shikimic acid analogs.

15 April 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
BBBeatriz Blanco
Beatriz Blanco
ASAntía Sedes
Antía Sedes
APAntonio Peón
Antonio Peón
JOJosé M. Otero
José M. Otero
MRMark J. Van Raaij
Mark J. Van Raaij
Concepción González-BelloConcepción González-Bello
Concepción González-Bello

6 April 2020 in Antibiotics
Verified
Journal Article
Open access
PDF file
AHAndrew J. Hayes
Andrew J. Hayes
JSJiulia Satiaputra
Jiulia Satiaputra
LSLouise M. Sternicki Louise M. Sternicki
Louise M. Sternicki Louise M. Sternicki
APAshleigh S. Paparella
Ashleigh S. Paparella
ZFZikai Feng
Zikai Feng
SPSteven Polyak
Steven Polyak
Biotin protein ligase (BPL) inhibitors are a novel class of antibacterial that target clinically important methicillin-resistant Staphylococcus aureus (S. aureus). In S. aureus, BPL is a bifunctional protein responsible for enzymatic biotinylation of two biotin-dependent enzymes, as well as serving as a transcriptional repressor that controls biotin synthesis and import. In this report, we investigate the mechanisms of action and resistance for a potent anti-BPL, an antibacterial compound, biotinyl-acylsulfamide adenosine (BASA). We show that BASA acts by both inhibiting the enzymatic activity of BPL in vitro, as well as functioning as a transcription co-repressor. A low spontaneous resistance rate was measured for the compound (<10−9) and whole-genome sequencing of strains evolved during serial passaging in the presence of BASA identified two discrete resistance mechanisms. In the first, deletion of the biotin-dependent enzyme pyruvate carboxylase is proposed to prioritize the utilization of bioavailable biotin for the essential enzyme acetyl-CoA carboxylase. In the second, a D200E missense mutation in BPL reduced DNA binding in vitro and transcriptional repression in vivo. We propose that this second resistance mechanism promotes bioavailability of biotin by derepressing its synthesis and import, such that free biotin may outcompete the inhibitor for binding BPL. This study provides new insights into the molecular mechanisms governing antibacterial activity and resistance of BPL inhibitors in S. aureus.